BidaskClub cut shares of NeoGenomics (NASDAQ:NEO) from a strong-buy rating to a buy rating in a research report report published on Tuesday morning.

Several other research analysts have also commented on the company. Scotiabank reissued an average rating and issued a $24.00 price objective on shares of NeoGenomics in a research report on Friday, November 16th. Zacks Investment Research raised NeoGenomics from a hold rating to a strong-buy rating and set a $21.00 price objective on the stock in a research report on Saturday, November 3rd. Benchmark set a $22.00 price objective on NeoGenomics and gave the company a buy rating in a research report on Thursday, November 1st. Raymond James lifted their target price on NeoGenomics from $16.00 to $21.00 and gave the stock a buy rating in a research report on Wednesday, October 31st. Finally, Craig Hallum lifted their target price on NeoGenomics from $17.00 to $22.00 and gave the stock a buy rating in a research report on Wednesday, October 31st. Two investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. NeoGenomics currently has a consensus rating of Buy and an average target price of $20.33.

NASDAQ:NEO opened at $14.78 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 3.98 and a current ratio of 4.13. NeoGenomics has a 12 month low of $7.08 and a 12 month high of $19.04. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of 246.33 and a beta of -0.01.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, October 30th. The medical research company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.02 by $0.03. NeoGenomics had a return on equity of 2.63% and a net margin of 1.70%. The company had revenue of $69.10 million for the quarter, compared to analyst estimates of $66.13 million. During the same period last year, the company posted $0.01 earnings per share. The firm’s revenue was up 16.8% compared to the same quarter last year. Equities research analysts anticipate that NeoGenomics will post 0.11 EPS for the current fiscal year.

In related news, insider Steven C. Jones sold 141,127 shares of NeoGenomics stock in a transaction dated Wednesday, November 14th. The stock was sold at an average price of $16.66, for a total value of $2,351,175.82. Following the completion of the transaction, the insider now directly owns 241,815 shares in the company, valued at $4,028,637.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Robert J. Shovlin sold 216,493 shares of NeoGenomics stock in a transaction dated Monday, November 12th. The stock was sold at an average price of $17.00, for a total value of $3,680,381.00. Following the completion of the transaction, the insider now owns 339,884 shares of the company’s stock, valued at $5,778,028. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 4,994,643 shares of company stock worth $83,771,998. Corporate insiders own 12.20% of the company’s stock.

A number of large investors have recently bought and sold shares of NEO. Cornerstone Wealth Management LLC bought a new stake in NeoGenomics in the second quarter valued at $528,000. Jennison Associates LLC boosted its holdings in NeoGenomics by 18.7% in the second quarter. Jennison Associates LLC now owns 43,736 shares of the medical research company’s stock valued at $573,000 after acquiring an additional 6,888 shares in the last quarter. C WorldWide Group Holding A S boosted its holdings in NeoGenomics by 25.1% in the second quarter. C WorldWide Group Holding A S now owns 239,681 shares of the medical research company’s stock valued at $3,142,000 after acquiring an additional 48,073 shares in the last quarter. Sei Investments Co. boosted its holdings in NeoGenomics by 18.4% in the second quarter. Sei Investments Co. now owns 58,141 shares of the medical research company’s stock valued at $762,000 after acquiring an additional 9,026 shares in the last quarter. Finally, EAM Investors LLC bought a new stake in NeoGenomics in the second quarter valued at $1,142,000. Institutional investors and hedge funds own 83.61% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

Recommended Story: How is a Moving Average Calculated?

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.